{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.7","upperLimit":"50.5","value":"44.2"},{"groupId":"OG001","lowerLimit":"19.9","upperLimit":"34.5","value":"27.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"APF18 was defined as the percentage of patients who were alive and progression free per RECIST 1.1 at 18 months after randomization per the Kaplan-Meier estimate of PFS at 18 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients in the durvalumab (MEDI4736) monotherapy group were to receive durvalumab 10 mg/kg Q2W via intravenous infusion for up to 12 months.","id":"OG000","title":"Durvalumab (MEDI4736)"},{"description":"Patients in the placebo group were to receive matching placebo for intravenous infusion Q2W for up to 12 months.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"FAS included all randomized patients, analyzed on an ITT basis.","reportingStatus":"POSTED","timeFrame":"Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~ 12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.","title":"Proportion of Patients Alive and Progression Free at 18 Months From (APF18) Based on BICR Assessments According to RECIST 1.1","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}